Who are varicella-5's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): recombinant subunit Herpes zoster vaccine, Zostavax vaccine, Zoster Vaccine Recombinant, recombinant adjuvanted zoster vaccine, Varicella Vaccine, Varicella vaccine live.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/varicella-5.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

varicella-5 — Competitive Intelligence Brief

varicella-5 (varicella-5) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine. Area: Immunology / Infectious Disease.

marketed Live attenuated vaccine Varicella-zoster virus Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

varicella-5 (varicella-5) — Changchun Keygen Biological Products Co., Ltd.. Varicella-5 is a live attenuated varicella-zoster virus vaccine that stimulates immune responses to prevent chickenpox infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
varicella-5 TARGET	varicella-5	Changchun Keygen Biological Products Co., Ltd.	marketed	Live attenuated vaccine	Varicella-zoster virus
recombinant subunit Herpes zoster vaccine	recombinant subunit Herpes zoster vaccine	University Health Network, Toronto	marketed	Recombinant subunit vaccine	Varicella-zoster virus glycoprotein E (gE)
Zostavax vaccine	Zostavax vaccine	Oklahoma Medical Research Foundation	marketed	Live attenuated vaccine	Varicella-zoster virus (VZV)
Zoster Vaccine Recombinant	Zoster Vaccine Recombinant	University of Colorado, Denver	marketed	Recombinant subunit vaccine	Varicella-zoster virus glycoprotein E (gE)
recombinant adjuvanted zoster vaccine	recombinant adjuvanted zoster vaccine	Wuerzburg University Hospital	marketed	Recombinant subunit vaccine with adjuvant	Varicella-zoster virus glycoprotein E (gE)
Varicella Vaccine	Varicella Vaccine	Novartis	marketed	Live attenuated vaccine	Varicella-zoster virus (VZV)
Varicella vaccine live	Varicella vaccine live	Sanofi Pasteur, a Sanofi Company	marketed	Live attenuated vaccine	Varicella-zoster virus (VZV)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine class)

GlaxoSmithKline · 19 drugs in this class
Merck Sharp & Dohme LLC · 11 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
PATH · 5 drugs in this class
Sanofi · 5 drugs in this class
Bandim Health Project · 5 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Beijing Center for Disease Control and Prevention · 2 drugs in this class
Aga Khan University · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). varicella-5 — Competitive Intelligence Brief. https://druglandscape.com/ci/varicella-5. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab